Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations

S Matsuura, N Inui, Y Ozawa… - Japanese Journal of …, 2011 - academic.oup.com
Objective There are few standard therapeutic options beyond second-line treatment. We
aimed to evaluate the efficacy and safety of erlotinib monotherapy as third-line …
被引用次数：19 相关文章

[引用][C] Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor …

S Matsuura, N Inui, Y Ozawa, Y Nakamura… - Japanese Journal of …, 2011 - cir.nii.ac.jp
Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell
Lung Cancer without Epidermal Growth Factor Receptor Mutations | CiNii Research CiNii …
[PDF] researchgate.net

[PDF][PDF] Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor …

S Matsuura, N Inui, Y Ozawa, Y Nakamura… - Jpn J Clin …, 2011 - researchgate.net
Objective: There are few standard therapeutic options beyond second-line treatment. We
aimed to evaluate the efficacy and safety of erlotinib monotherapy as third-line …

Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations

S Matsuura, N Inui, Y Ozawa… - … journal of clinical …, 2011 - pubmed.ncbi.nlm.nih.gov
Objective There are few standard therapeutic options beyond second-line treatment. We
aimed to evaluate the efficacy and safety of erlotinib monotherapy as third-line …

Phase II Study Of Erlotinib As Third-Line Monotherapy In Patients With Advanced Non-Small-Cell Lung Cancer Without Epidermal Growth Factor Receptor Mutations

S Matsuura, N Inui, Y Ozawa, T Shirai… - C43. LUNG CANCER …, 2012 - atsjournals.org
PURPOSE: There are few standard therapeutic options beyond second-line treatment. We
aimed to evaluate the efficacy and safety of erlotinib monotherapy as third-line …

Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.

S Matsuura, N Inui, Y Ozawa, Y Nakamura… - Japanese Journal of …, 2011 - europepmc.org
Objective There are few standard therapeutic options beyond second-line treatment. We
aimed to evaluate the efficacy and safety of erlotinib monotherapy as third-line …